计算溶液所需的质量、体积或浓度。
Spartalizumab (anti-PD-1) (Ab169299) - ELISA
Immobilized Recombinant Human PD-1 Protein at 1 μg/mL can bind Spartalizumab (anti-PD-1) (Ab169299) with the EC₅₀ of 39.7 ng/mL.
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
Ab169299-100μg |
100μg |
现货 ![]() |
| |
Ab169299-1mg |
1mg |
现货 ![]() |
| |
Ab169299-5mg |
5mg |
现货 ![]() |
| |
Ab169299-10mg |
10mg |
期货 ![]() |
|
产品名称 | Spartalizumab (anti-PD-1), 程序性细胞死亡 1 (CD279) 抗体 |
---|---|
别名 | 斯帕妥珠单抗(抗-PD-1) |
英文别名 | hPD-1 | Protein PD-1 |
规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
宿主种属 | 人(Human) |
特异性 | PDCD1 |
应用 | ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt |
种属反应性 | 人(Human),食蟹猴(Cynomolgus monkey) |
偶联 | Unconjugated |
作用类型 | 拮抗剂 |
作用机制 | 程序性细胞死亡 1 (CD279) 抗体 |
抗体类型 | Primary antibody |
---|---|
克隆类型 | 重组抗体 |
Format | Whole IgG |
亚型 | Human IgG4SP |
轻链亚型 | kappa |
SDS-PAGE | 28.1 kDa (Light Chain) & 51.7 kDa (Heavy Chain), under reducing conditions; 175.9 kDa, under non-reducing conditions. |
纯化方法 | Protein A purified |
纯度 | >95% |
来源 | CHO supernatant |
物理外观 | Liquid |
储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
防腐剂 | No |
浓度 | 见COA |
储存温度 | -80℃储存,避免反复冻融 |
运输条件 | 超低温冰袋运输 |
稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
CAS编号和信息 | 1935694-88-4 |
分子类型 | 抗体 |
Spartalizumab (anti-PD-1) (Ab169299) - ELISA
Immobilized Recombinant Human PD-1 Protein at 1 μg/mL can bind Spartalizumab (anti-PD-1) (Ab169299) with the EC₅₀ of 39.7 ng/mL.
Spartalizumab (anti-PD-1) (Ab169299) - SEC
The purity of Spartalizumab (anti-PD-1) (Ab169299) is more than 95% verified by HPLC.
Spartalizumab (anti-PD-1) (Ab169299) - ELISA
Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Spartalizumab (anti-PD-1) (Ab169299) with the EC50 of 13.27 ng/mL.
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
批号(Lot Number) | 证书类型 | 日期 | 货号 |
---|---|---|---|
![]() |
分析证书 | 24-10-25 | Ab169299 |
![]() |
分析证书 | 24-10-25 | Ab169299 |
![]() |
分析证书 | 24-10-25 | Ab169299 |
![]() |
分析证书 | 23-12-13 | Ab169299 |
¥669.90
¥169.90
¥599.90
¥199.90
¥209.90
¥669.90
¥569.90
¥329.90
¥499.90
¥269.90
¥399.90
¥899.90
¥199.90
¥669.90
¥559.90
¥559.90
¥579.90
¥379.90
¥539.90
¥719.90
1. Kline J, Gajewski TF. (2010) Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.. Curr Opin Investig Drugs, 11 (12): (1354-9). [PMID:21154117] [10.1021/op500134e] |
2. Hall RD, Gray JE, Chiappori AA. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.. Cancer Control, 20 (1): (22-31). [PMID:23302904] [10.1021/op500134e] |
3. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al.. (2017) Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.. Mol Cancer Ther, 16 (5): (861-870). [PMID:28265006] [10.1021/op500134e] |
4. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips. (1997-10-23) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.. Gene, 197 ((1-2)): (177-187). [PMID:9332365] |
5. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T.. (1994) Structure and chromosomal localization of the human PD-1 gene (PDCD1).. Genomics, [PMID:7851902] |
6. Prokunina, Ludmila L and 23 more authors.. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.. Nature genetics, [PMID:12402038] |
7. Topalian, Suzanne L SL and 29 more authors.. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.. The New England journal of medicine, (28): [PMID:22658127] |
8. Robert, Caroline C and 27 more authors.. (2015) Nivolumab in previously untreated melanoma without BRAF mutation.. The New England journal of medicine, (22): [PMID:25399552] |
9. McDermott, J J and Jimeno, A A.. (2015) Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.. Drugs of today (Barcelona, Spain : 1998), [PMID:25685857] |
10. Na, Zhenkun and 6 more authors.. (2017) Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.. Cell research, [PMID:27325296] |
11. Pascolutti, Roberta R and 6 more authors.. (2016) Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.. Structure (London, England : 1993), (4): [PMID:27618663] |
12. Horita, Shoichiro S and 5 more authors.. (2016) High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.. Scientific reports, (13): [PMID:27734966] |
13. Tan, Shuguang S and 15 more authors.. (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.. Nature communications, (6): [PMID:28165004] |
14. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ.. (2018) PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.. Gene, (5): [PMID:28951311] |